Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
Company profile
Ticker
AGTC
Exchange
Website
CEO
Susan Washer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
AGTC stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
12 Dec 22
EFFECT
Notice of effectiveness
7 Dec 22
EFFECT
Notice of effectiveness
7 Dec 22
EFFECT
Notice of effectiveness
7 Dec 22
25-NSE
Exchange delisting
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
Transcripts
AGTC
Earnings call transcript
2022 Q2
14 Feb 22
AGTC
Earnings call transcript
2021 Q4
24 Sep 21
AGTC
Earnings call transcript
2021 Q4
24 Sep 21
AGTC
Earnings call transcript
2021 Q3
18 May 21
AGTC
Earnings call transcript
2021 Q2
11 Feb 21
AGTC
Earnings call transcript
2020 Q4
9 Sep 20
AGTC
Earnings call transcript
2020 Q3
13 May 20
AGTC
Earnings call transcript
2007 Q1
9 Jan 20
AGTC
Earnings call transcript
2020 Q1
13 Nov 19
AGTC
Earnings call transcript
2019 Q4
26 Sep 19
Latest ownership filings
SC 13G/A
Beryl Capital Management LLC
14 Feb 23
SC 13D
Tetragon Financial Management LP
8 Dec 22
4
James A. Jr. Robinson
1 Dec 22
4
ANNE VANLENT
1 Dec 22
4
James Rosen
1 Dec 22
4
William Aliski
1 Dec 22
4
EDWARD HURWITZ
1 Dec 22
4
Yehia Hashad
1 Dec 22
4
Scott Koenig
1 Dec 22
4
Gerald Anthony Reynolds
1 Dec 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.16 mm | 37.16 mm | 37.16 mm | 37.16 mm | 37.16 mm | |
Cash burn (monthly) | 1.89 mm | 5.78 mm | 5.59 mm | 5.35 mm | 5.49 mm | |
Cash used (since last report) | 33.92 mm | 103.83 mm | 100.42 mm | 96.01 mm | 98.55 mm | |
Cash remaining | 3.24 mm | -66.67 mm | -63.25 mm | -58.84 mm | -61.39 mm | |
Runway (months of cash) | 1.7 | -11.5 | -11.3 | -11.0 | -11.2 |
Institutional ownership, Q3 2022
22.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 7 |
Closed positions | 15 |
Increased positions | 10 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 13.83 mm |
Total shares | 15.10 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Portolan Capital Management | 1.60 mm | $435.00 k |
Vanguard | 1.48 mm | $401.00 k |
Millennium Management | 1.46 mm | $395.00 k |
Interwest Partners Viii | 1.40 mm | $2.67 mm |
Interwest Venture Management | 1.40 mm | $381.00 k |
Kingdon Capital Management, L.L.C. | 1.23 mm | $333.00 k |
Intersouth Partners Vi | 1.21 mm | $4.97 mm |
Renaissance Technologies | 1.14 mm | $309.00 k |
BLK Blackrock | 918.38 k | $249.00 k |
Integrated Core Strategies | 717.36 k | $2.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Nov 22 | Gerald Anthony Reynolds | Common Stock | Sale back to company | Dispose D | No | No | 0 | 42,500 | 0.00 | 0 |
30 Nov 22 | Gerald Anthony Reynolds | Common Stock | Dispose U | No | No | 0 | 8,506 | 0.00 | 42,500 | |
30 Nov 22 | Gerald Anthony Reynolds | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.7 | 34,500 | 127.65 k | 0 |
30 Nov 22 | Gerald Anthony Reynolds | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.5 | 30,000 | 165.00 k | 0 |
30 Nov 22 | Gerald Anthony Reynolds | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.28 | 50,000 | 164.00 k | 0 |
30 Nov 22 | Aliski William | Common Stock | Dispose U | No | No | 0 | 8,500 | 0.00 | 0 | |
30 Nov 22 | Aliski William | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.17 | 14,000 | 30.38 k | 0 |
30 Nov 22 | Aliski William | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.72 | 12,000 | 56.64 k | 0 |
30 Nov 22 | Aliski William | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.02 | 10,000 | 30.20 k | 0 |
30 Nov 22 | Aliski William | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.9 | 10,000 | 69.00 k | 0 |